AN2 Therapeutics(ANTX) - 2025 Q4 - Annual Results

Exhibit 99.1 "Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2's boron chemistry pipeline and our commitment to addressing serious, underserved diseases. It also represents one of three proof-of-concept catalysts we believe we are well positioned to achieve in the next two years, including the Phase 2 investigator- initiated trial in M. abscessus complex lung disease and a Phase 2 proof-of-concept study in chronic Chaga ...